These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34821219)

  • 1. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
    Zhu J; Tang C; Cong Z; Yuan F; Cai X; Yang J; Ma C
    Endocr Relat Cancer; 2021 Dec; 29(2):33-46. PubMed ID: 34821219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
    Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
    BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
    Tang C; Zhu J; Yuan F; Yang J; Cai X; Ma C
    Mol Neurobiol; 2021 Dec; 58(12):6170-6185. PubMed ID: 34463926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
    J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
    Yao H; Tang H; Zhang Y; Zhang QF; Liu XY; Liu YT; Gu WT; Zheng YZ; Shang HB; Wang Y; Huang JY; Wei YX; Zhang X; Zhang J; Wu ZB
    Cancer Lett; 2019 Sep; 459():135-144. PubMed ID: 31176743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
    Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
    Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
    Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.
    Lin SJ; Leng ZG; Guo YH; Cai L; Cai Y; Li N; Shang HB; Le WD; Zhao WG; Wu ZB
    Oncotarget; 2015 Nov; 6(36):39329-41. PubMed ID: 26513171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
    Liu YT; Liu F; Cao L; Xue L; Gu WT; Zheng YZ; Tang H; Wang Y; Yao H; Zhang Y; Xie WQ; Ren BH; Xiao ZH; Nie YJ; Hu R; Wu ZB
    Acta Neuropathol; 2020 Sep; 140(3):377-396. PubMed ID: 32572597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine.
    Lin SJ; Wu ZR; Cao L; Zhang Y; Leng ZG; Guo YH; Shang HB; Zhao WG; Zhang X; Wu ZB
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3692-3703. PubMed ID: 28973192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
    Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
    BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactinomas, cabergoline, and pregnancy.
    Glezer A; Bronstein MD
    Endocrine; 2014 Sep; 47(1):64-9. PubMed ID: 24985062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
    Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D
    Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
    Huang HY; Lin SJ; Zhao WG; Wu ZB
    Metab Brain Dis; 2018 Jun; 33(3):969-976. PubMed ID: 29546691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
    Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.